Education
About Us
Working with TipRanks
Follow Us
Igc Pharma, Inc. (IGC)
:IGC
IGC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $0.91
Previous CloseN/A
Volume646.33K
Average Volume (3M)394.28K
Market Cap
$25.74M
Enterprise Value$31.21M
Total Cash (Recent Filing)$470.00K
Total Debt (Recent Filing)$146.00K
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Jun 18, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding79,685,165
10 Day Avg. Volume467,986
30 Day Avg. Volume394,283
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.82
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.58
Enterprise Value/Ebitda-4.05
Forecast
1Y Price Target
$4.25Price Target Upside1228.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.
Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.
Strategic ExpansionThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.
Bears Say
Investment RisksThe current valuation is considered attractive, with a raised 12-month price target to $4.00, indicating significant upside potential from the current share price.
Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.
---
Ownership Overview
25.28% Insiders
1.51% Mutual Funds
0.15% Other Institutional Investors
72.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IGC FAQ
What was Igc Pharma, Inc.’s price range in the past 12 months?
Igc Pharma, Inc. lowest stock price was $0.26 and its highest was $0.91 in the past 12 months.
What is Igc Pharma, Inc.’s market cap?
Igc Pharma, Inc.’s market cap is $25.74M.
When is Igc Pharma, Inc.’s upcoming earnings report date?
Igc Pharma, Inc.’s upcoming earnings report date is Jun 18, 2025 which is in 85 days.
How were Igc Pharma, Inc.’s earnings last quarter?
Igc Pharma, Inc. released its earnings results on Feb 18, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.03 by $0.01.
Is Igc Pharma, Inc. overvalued?
According to Wall Street analysts Igc Pharma, Inc.’s price is currently Undervalued.
Does Igc Pharma, Inc. pay dividends?
Igc Pharma, Inc. does not currently pay dividends.
What is Igc Pharma, Inc.’s EPS estimate?
Igc Pharma, Inc.’s EPS estimate is -0.02.
How many shares outstanding does Igc Pharma, Inc. have?
Igc Pharma, Inc. has 79,685,165 shares outstanding.
What happened to Igc Pharma, Inc.’s price movement after its last earnings report?
Igc Pharma, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.03. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Igc Pharma, Inc.?
Currently, no hedge funds are holding shares in IGC
---
Company Description
Igc Pharma, Inc.
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand. The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts. It operates in the United States, India, Colombia, and Hong Kong. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
---
IGC Stock 12 Month Forecast
Average Price Target
$4.25
▲(1228.13% Upside)
Technical Analysis
Best Analysts Covering IGC
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-8.30%
reiterated a buy rating last month
Copying Edward Woo's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -8.30% per trade.
---